Startup Trends: 5 emerging high-valued healthcare companies
The private healthcare sector continues to indicate high growth potential. U.S. venture capital investments into these companies increased to $23 billion in 2024, up from $20 billion in 2023, according to a new report released this month by Silicon Valley Bank.
Firms within the sector continue to emerge with state-of-the-art digital and AI features to improve their products and outcomes for customers. Here are five healthcare companies listed on Forge that are showing strong innovations in their respective areas of specialty.
Hinge Health, digital clinic
Hinge Health, a San Francisco-based company, is a digital clinic that specializes in the treatment of and therapies for muscle and joint ailments. According to its website, its team of specialists includes physical therapists, physicians, and health coaches that aim to reduce the need for surgeries. In September 2024, the company enlisted Morgan Stanley to guide it towards a confidential S-1 filing for a potential IPO.
Hinge Health’s Forge Price™ was $31.00 as of January 8, 2025, which implies a valuation of $2.48 billion. The healthcare firm’s investors include Coatue Management, Bessemer Ventures Partners, Insight Partners, and Tiger Global Management.
Neuralink, brain-machine interfaces
Neuralink, a Fremont, California-based company, is the researcher and developer of brain-machine interfaces designed to help people with paralysis. Founded in 2016 by Elon Musk, Max Hodak, and Paul Morolla, the firm most recently tested its brain chip technology for two patients in the U.S. with FDA approval and is now approved to start testing its technology in Canada.
Neuralink’s Forge Price™ is $44.88 as of January 8, 2025, which implies a valuation of $8.13 billion. The private healthcare company’s investors include Founders Fund, Google Ventures, Valor Equity Partners, and Craft Ventures.
Altos Labs, cell rejuvenating therapeutics
Altos Labs, a Redwood City, California-based company specializes in biotechnology innovations designed to rejuvenate cells to treat and cure humans of various diseases. The company is also looking into new ways to slow the aging process. The startup most recently announced its Altos Institute of Computation, whose mission is to “decode the language of biological resilience at the cell, organ, and organism levels.”
Altos Labs’ latest price per share was $25.02 based on its latest funding round in February 2024, which placed the company’s post-money valuation at $6.33 billion. The firm has a notable slate of board of directors and advisors that include Nobel Laureates and scientific leaders, according to its website. Its investors include Arch Venture Partners, Foresite Capital, and Mubadala Investment Company.
Devoted Health, senior healthcare guidance
Devoted Health, a Waltham, Massachusetts-based company focuses on providing insurance and healthcare advice for seniors. The firm relies on Medicare Advantage Plans as part of its insurance provider for its members, and was most recently named U.S. News and World Report’s “Best Insurance Companies for Medicare Advantage in 2025.” The company was one of only four in the best “overall” category and was recognized for its service across ten U.S. states. Devoted Health was among the startups listed on Forge with the highest fundraising round for 2024.
Devoted Health’s latest price per share was $56.25 based on its last funding round in August 2024 which placed the company’s post-money valuation at $13.03 billion. The firm’s investors include Andreessen Horowitz, Softbank, Venrock, and Maverick Ventures.
Resilience, a biopharmaceutical manufacturer
Resilience, a San Diego, California-based company is a biopharmaceutical manufacturer that focuses on solutions to treat various human ailments through gene and cell therapies and vaccines. In recent years, the firm has established partnerships with known brands such as Labcorp and AstraZeneca to accelerate its therapeutics. The company has also advanced the research and development of stem cells to treat a variety of diseases through a partnership with biopharma company Pluristyx.
Resilience’s latest price per share was $60.73 based on its June 2022 funding round which placed the firm’s post-money valuation at $8.84 billion. It was also one of Forge’s top funding startups of 2022. Its list of investors includes ARCH Venture Partners, 8VC, and Strategic Innovation Fund.
